Fisetin Tested as Senolytic Treatment to Reduce COVID-19 Complications
A Phase 2 pilot trial investigates whether the natural senolytic compound fisetin can reduce dysfunction and complications in COVID-19 patients.
Summary
Researchers at the Mayo Clinic, led by renowned aging scientist James Kirkland, conducted a Phase 2 pilot trial to determine whether fisetin — a naturally occurring flavonoid with senolytic properties — could reduce complications in people infected with COVID-19. Senolytics are compounds that selectively clear senescent cells, which are dysfunctional 'zombie' cells that accumulate with age and drive inflammation. The hypothesis was that by reducing the senescent cell burden during acute COVID-19 infection, fisetin might dampen the inflammatory cascade responsible for severe outcomes. The trial compared fisetin against placebo in COVID-19 patients and has since been completed. Full results have not been published in the abstract, but the study represents an important early test of senolytic therapy in an acute infectious disease context.
Detailed Summary
Senescent cells — aged, dysfunctional cells that resist normal death — accumulate in tissues and secrete a cocktail of inflammatory signals known as the senescence-associated secretory phenotype (SASP). This chronic low-grade inflammation is a hallmark of biological aging and has been implicated in worsening outcomes across a range of diseases, including COVID-19. The COVFIS-HOME trial was designed to test whether clearing senescent cells with a senolytic agent could reduce the severity of COVID-19 complications.
Fisetin, a flavonoid found naturally in strawberries, apples, and onions, has emerged as one of the most promising senolytic compounds in preclinical research. Unlike synthetic senolytics, fisetin is widely available as a supplement and has a favorable safety profile, making it an attractive candidate for rapid clinical testing during the pandemic. The trial was sponsored by James L. Kirkland, MD, PhD, one of the world's leading researchers in cellular senescence and senolytics.
This Phase 2 randomized, placebo-controlled pilot study enrolled COVID-19 patients and administered either fisetin or placebo, with the primary goal of assessing whether fisetin could alleviate dysfunction and decrease complications associated with the infection. The study has been completed, though detailed outcome data were not available in the abstract reviewed here.
The implications of this trial extend well beyond COVID-19. If fisetin demonstrates efficacy in reducing inflammatory complications in an acute infectious disease setting, it would provide proof-of-concept that senolytic therapy can be deployed rapidly in clinical contexts — a significant step toward broader therapeutic use in aging-related conditions.
However, this summary is based solely on the trial registration abstract, and full results including efficacy endpoints, adverse events, and statistical outcomes are not yet available for review. Caution is warranted in drawing conclusions until peer-reviewed data are published.
Key Findings
- Phase 2 pilot trial tested fisetin as a senolytic intervention to reduce COVID-19 complications.
- Trial was sponsored by James Kirkland, a leading senescence researcher at Mayo Clinic.
- Fisetin targets senescent cells whose inflammatory output may worsen COVID-19 severity.
- The study is completed, but full efficacy and safety results are not yet publicly available.
- Positive results could support broader use of senolytics in acute inflammatory conditions.
Methodology
This was a Phase 2 randomized, placebo-controlled pilot study comparing fisetin versus placebo in COVID-19 patients. The trial was registered on ClinicalTrials.gov (NCT04771611) and has been completed. Specific sample size, dosing regimen, and primary endpoints were not detailed in the available abstract.
Study Limitations
This summary is based on the trial registration abstract only, as the full study data are not openly available; no efficacy or safety outcomes can be reported. The pilot design limits statistical power and generalizability. Without published peer-reviewed results, the clinical significance of this trial remains uncertain.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.